Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jan;27(1):61-69.
doi: 10.1038/s41431-018-0254-8. Epub 2018 Sep 25.

Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression

Małgorzata Rydzanicz  1 , Małgorzata Wachowska  2 , Erik C Cook  3 , Paweł Lisowski  4   5 , Bożena Kuźniewska  6 , Krystyna Szymańska  7 , Sebastian Diecke  5 , Alessandro Prigione  5 , Krzysztof Szczałuba  1 , Aleksandra Szybińska  8 , Agnieszka Koppolu  1   9 , Victor Murcia Pienkowski  1   9 , Joanna Kosińska  1 , Małgorzata Wiweger  8 , Grażyna Kostrzewa  1 , Małgorzata Brzozowska  10 , Dorota Domańska-Pakieła  11 , Elżbieta Jurkiewicz  12 , Piotr Stawiński  1 , Agnieszka Gromadka  13 , Piotr Zielenkiewicz  13 , Urszula Demkow  2 , Magdalena Dziembowska  6 , Jacek Kuźnicki  8 , Trevor P Creamer  3 , Rafał Płoski  14
Affiliations
Case Reports

Novel calcineurin A (PPP3CA) variant associated with epilepsy, constitutive enzyme activation and downregulation of protein expression

Małgorzata Rydzanicz et al. Eur J Hum Genet. 2019 Jan.

Abstract

PPP3CA encodes calmodulin-binding catalytic subunit of calcineurin, a ubiquitously expressed calcium/calmodulin-regulated protein phosphatase. Recently de novo PPP3CA variants were reported as a cause of disease in 12 subjects presenting with epileptic encephalopathy and dysmorphic features. We describe a boy with similar phenotype and severe early onset epileptic encephalopathy in whom a novel de novo c.1324C>T (p.(Gln442Ter)) PPP3CA variant was found by whole exome sequencing. Western blot experiments in patient's cells (EBV transformed lymphocytes and neuronal cells derived through reprogramming) indicate that despite normal mRNA abundance the protein expression level is strongly reduced both for the mutated and wild-type protein. By in vitro studies with recombinant protein expressed in E. coli we show that c.1324C>T (p.(Gln442Ter)) results in constitutive activation of the enzyme. Our results confirm the role of PPP3CA defects in pathogenesis of a distinct neurodevelopmental disorder including severe epilepsy and dysmorphism and provide further functional clues regarding the pathogenic mechanism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Facial features of proband. Slight dysmorphia consisting mainly of microretrognathia at age 2 weeks (a), and then evolving into slightly turricephalic skull, hypertelorism, wide nasal alae, relative macrostomia with open mouth and full lips as well as microretrognathia at ages of 6 months (b) and 7 years (c)
Fig. 2
Fig. 2
Analysis of Calcineurin Aα protein levels cells from patient with identified variant in PPP3CA gene and control subjects using western blotting (WB). Specific antibody recognizing both normal and mutant form (truncated protein, lacking autoinhibitory domain) of calcineurin Aα was used (Abcam #52761, 1:1000 in 1% milk). A Representative example of analysis in immortalized B-lymphocytes (left-protein loading shown by TGX stain-free SDS-PAGE gel). B Quantification of WB shown in A done for WT CaN protein, data presented as mean fold change relative to control subject, three independent cultures of each cell line were analyzed. Error bar indicates SEM. C Analysis in induced neuronal cells (lymphoblasts are shown for comparison). Arrows indicate truncated protein.
Fig. 3
Fig. 3
Phosphatase activity for wild-type CaN (solid lines) and CaN∆442 (dashed lines). Kinetics for dephosphorylation of pRII in the a absence and b presence of CaM
Fig. 4
Fig. 4
Structure of human calcineurin, isoform (PDBID 1AUI) [23]. CnA (from PPP3CA) is shown in dark blue and CnB (from PPP3R1) in grey, with the catalytic iron ion as an orange sphere and the catalytic zinc ion as a pale blue sphere. Calcium ions bound to CnB are shown as grey spheres. The intrinsically disordered regulatory domain (RD) was generated using MODELLER [24]. The variant identified in this work, c.1324C>T (p.(Gln442Ter)), is shown in red, variants identified by Myers et al. [7] and Deciphering Developmental Disorders Study [20] are purple, those identified by Mizuguchi et al. [8] in yellow, and c.275A>G (p.(His92Arg)), reported by both the latter two groups, in green. The top inset shows variants that occur in the autoinhibitory domain (AID) and the bottom inset shows those clustered around the active site
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev. 2000;80:1483–521. doi: 10.1152/physrev.2000.80.4.1483. - DOI - PubMed
    1. Wen Yuetao, Fu Pengfei, Wu Kunlun, Si Kaichuang, Xie Yanfeng, Dan Wei, Zhan Yan, Shi Quanhong. Inhibition of Calcineurin A by FK506 Suppresses Seizures and Reduces the Expression of GluN2B in Membrane Fraction. Neurochemical Research. 2017;42(8):2154–2166. doi: 10.1007/s11064-017-2221-0. - DOI - PubMed
    1. Eckel R, Szulc B, Walker MC, Kittler JT. Activation of calcineurin underlies altered trafficking of alpha2 subunit containing GABAA receptors during prolonged epileptiform activity. Neuropharmacology. 2015;88:82–90. doi: 10.1016/j.neuropharm.2014.09.014. - DOI - PMC - PubMed
    1. Freire-Cobo Carmen, Sierra-Paredes Germán, Freire Manuel, Sierra-Marcuño Germán. The Calcineurin Inhibitor Ascomicin Interferes with the Early Stage of the Epileptogenic Process Induced by Latrunculin A Microperfusion in Rat Hippocampus. Journal of Neuroimmune Pharmacology. 2014;9(5):654–667. doi: 10.1007/s11481-014-9558-9. - DOI - PubMed
    1. Sierra-Paredes G, Sierra-Marcuno G. Ascomycin and FK506: pharmacology and therapeutic potential as anticonvulsants and neuroprotectants. CNS Neurosci Ther. 2008;14:36–46. - PMC - PubMed

Publication types

-